148
Participants
Start Date
September 7, 2011
Primary Completion Date
December 31, 2016
Study Completion Date
July 30, 2019
BAY94-9343
BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
BAY94-9343 (Expansion)
BAY94-9343 was administered intravenously in this study. The dose for this expansion cohort was 5.5mg/kg administered as a 1 hour infusion every 21 days.
BAY94-9343 (1.8 mg/kg)
BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
BAY94-9343 (2.2 mg/kg)
BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
Bethesda
Nashville
Detroit
Chicago
Oklahoma City
Dallas
Houston
New Haven
Lead Sponsor
Bayer
INDUSTRY